ACADIA Pharmaceuticals beats Q2 earnings and revenue estimates, raising 2026 revenue forecast and price target.

ACADIA Pharmaceuticals reported strong Q2 2026 results, with earnings of $0.18 per share beating estimates by 200% and revenues of $307.96 million surpassing forecasts by nearly 5%. Driven by increased sales of key drugs Daybue and Nuplazid, the company raised its 2026 revenue forecast to $1.24-$1.30 billion. Citigroup reaffirmed a "Buy" rating and raised the price target from $35 to $39, reflecting confidence in ACADIA's growth prospects and solid financial performance.